Clinical trials
Neoplasm Recurrence, Local clinical trials
Below are recruiting neoplasm recurrence, local clinical trials, each written for real people, not researchers. We’re tracking 65 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06305299RecruitingPhase 1
CAR-T cell therapy for ovarian cancer
This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.
Chapel Hill, North CarolinaAges 18 years+ - NCT06502743RecruitingPhase 2
Study of chemotherapy and pembrolizumab with or without nesuparib for endometrial cancer
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Kyeonggi-doAges 19 years+ - NCT07010939Recruiting
Side effects and quality of life after breast cancer treatment in China
This study looks at how local treatments like surgery, chemotherapy, radiation, hormone therapy, or targeted therapy affect your side effects and quality of life. Researchers want to learn from women with early-stage breast cancer to improve care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT02819882Recruiting
Registry study for advanced or metastatic breast cancer
This study collects health and treatment information from people with breast cancer that cannot be fully removed by surgery or that has spread to other parts of the body. It may help researchers better understand which treatments are used and how people do over time.
Elche, AlicanteAges 18 years+ - NCT06353906RecruitingPhase 2
Chemo plus immunotherapy for advanced penile cancer
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
LeuvenAges 18 years+ - NCT01834001Recruiting
MRI checks how prostate cancer responds to radiation
This study uses MRI scans to see how prostate cancer changes after radiation treatment, especially in the local (prostate-area) response. It may help doctors better judge treatment effectiveness and plan care more precisely.
Bethesda, MarylandAges 18–120 - NCT01365169Recruiting
How activity level and daily function relate to cancer survival
This study looks at how physical activity (movement during the day) and a clinician-rated “day-to-day function” score relate to overall survival in people with certain cancers. It may help doctors understand who benefits most from activity-focused care and better monitoring.
Houston, TexasAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT05705492RecruitingPhase 2
Olanzapine to help cancer-related weight and appetite loss
This Phase 2 trial tests whether olanzapine can help people with advanced cancer who are losing weight and not eating enough. It looks for improvements in appetite and weight while you receive your first-line palliative cancer treatment.
Portland, OregonAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06150417RecruitingPhase 2
Study of extra radiation for prostate cancer spread to few spots
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
Cleveland, OhioAges 18 years+ - NCT06265285RecruitingPhase 2
Nivolumab at home vs. clinic for cancer treatment
This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.
Jacksonville, FloridaAges 18 years+ - NCT02886104Recruiting
Surgery versus local ablation for certain liver metastases
This trial compares two ways to treat colorectal cancer that has spread to the liver: removing liver tumors with surgery versus destroying them in place with local ablation. It may help doctors learn which approach works best for people whose disease can be fully treated and who have enough healthy liver left.
Guangzhou, GuangdongAges 18–80 - NCT06023862RecruitingPhase 2
Study of dostarlimab and bevacizumab for recurrent clear cell cancer
This trial tests a drug called dostarlimab alone or with bevacizumab compared to standard chemotherapy for women whose clear cell cancer of the ovary, uterus, cervix, vagina, or vulva has come back within a year of platinum chemotherapy. The goal is to see if these newer treatments can help control the cancer better.
Clayton, Clayton Rd.Ages 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT05984576Recruiting
Chemo and radiation for recurrent rectal cancer after prior pelvic radiation
This study looks at combining total neoadjuvant therapy (chemotherapy and radiation) for rectal cancer that has come back in the pelvis after earlier radiation. It aims to see if this treatment approach can help control the disease and improve outcomes in patients with limited spread that can potentially be removed or treated.
RomeAges 18 years+ - NCT07137416RecruitingPhase 1
Testing a new combination of cancer drugs for HER2-positive tumors and breast cancer
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
Boston, MassachusettsAges 18 years+
Hear when a new Neoplasm Recurrence, Local trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neoplasm recurrence, local?
- Yes. Clin2 currently lists 65 recruiting neoplasm recurrence, local studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neoplasm recurrence, local trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neoplasm recurrence, local trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.